pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
310
stories
2h
Could we one day vaccinate against every cancer?
stat
6h
STAT+: Hospital and pharmaceutical prices are smothering America’s businesses
stat
6h
STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen
stat
10h
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
10h
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
2d
NIH rolling out streamlined website to help public find information more easily
stat
3d
Foghorn cuts 40% of workforce
biospace
3d
How to Choose a Biologics CDMO: 4 Criteria That Matter the Most
fiercebiotech
3d
Abbott launches SimpleScreen CRC blood test in the US
fiercebiotech
3d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
4d
Lawmakers hear mixed opinions on psychedelics credentialing
endpoints
4d
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
4d
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
biospace
6d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
6d
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
biopharma dive
6d
uniQure stock crashes as Huntington’s gene therapy data weaken
fiercebiotech
6d
Opinion: Child health is the national security crisis we keep ignoring
stat
7d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
7d
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
7d
6 immunology targets to sustain a mammoth I&I market
biospace
7d
Convergence: CBER expert offers tips for effective BLA submissions
raps
9d
Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?
stat
9d
After COVID, biomanufacturing tackles preparedness and commercialization challenges
biospace
10d
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
11d
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
biospace
11d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
11d
New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption
fiercebiotech
12d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
12d
Roche kidney drug's Phase 3 win sets up path to accelerated approval
endpoints
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
← prev
page 1 of 11
next →
